Zeke Capital Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Zeke Capital Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,783	Closed	-$348K	–	359
2021 Q1	$348K	Sell	3,783 -747	-16%	-$63K	0.02%	179
2020 Q4	$331K	Buy	+4,530	New	+$337K	0.03%	177
2018 Q3	–	Sell	-13,212	Closed	-$219K	–	785
2018 Q2	$219K	Hold	13,212	–	–	0.02%	518
2018 Q1	$188K	Buy	13,212 +1,779	+16%	+$26.3K	0.02%	588
2017 Q4	$167K	Buy	+11,433	New	+$161K	0.02%	524

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Zeke Capital Advisors's HZNP Position: Q2 2021 in Review

Zeke Capital Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2021, closing a stake of 3,783 shares — an estimated $348K sold.

Zeke Capital Advisors first reported a position in HZNP in Q4 2017 and held it in 5 quarters. The position peaked at $348K in Q1 2021. 526 funds tracked by Wall St. Rank hold HZNP as of Q2 2021.

Zeke Capital Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2021 after selling out during the quarter.
Zeke Capital Advisors sold 3,783 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2021, an estimated $348K.
Zeke Capital Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 5 quarters.
Zeke Capital Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $348K in Q1 2021.
526 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2021.

Based on Zeke Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.